Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Gross Margin % : 69.39% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Biocytogen Pharmaceuticals (Beijing) Co's Gross Profit for the six months ended in Dec. 2023 was HK$296.1 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Revenue for the six months ended in Dec. 2023 was HK$426.7 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin % for the quarter that ended in Dec. 2023 was 69.39%.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin % or its related term are showing as below:

HKSE:02315' s Gross Margin % Range Over the Past 10 Years
Min: 65.86 Med: 70.19 Max: 73.38
Current: 70.59

During the past 4 years, the highest Gross Margin % of Biocytogen Pharmaceuticals (Beijing) Co was 73.38%. The lowest was 65.86%. And the median was 70.19%.

HKSE:02315's Gross Margin % is ranked better than
62.38% of 747 companies
in the Biotechnology industry
Industry Median: 60.43 vs HKSE:02315: 70.59

Biocytogen Pharmaceuticals (Beijing) Co had a gross margin of 69.39% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Biocytogen Pharmaceuticals (Beijing) Co was 0.00% per year.

Biocytogen Pharmaceuticals (Beijing) Co Gross Margin % Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Gross Margin % Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Gross Margin %

65.86

69.79

73.38

70.59

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross Margin %	Get a 7-Day Free Trial			70.86	72.87	73.76	72.01	69.39

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin %

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin % falls into.

Biocytogen Pharmaceuticals (Beijing) Co Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	553.5	/	784.143
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(784.143 - 230.654)	/	784.143
	=	70.59 %

Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	296.1	/	426.657
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(426.657 - 130.604)	/	426.657
	=	69.39 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Biocytogen Pharmaceuticals (Beijing) Co had a gross margin of 69.39% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Biocytogen Pharmaceuticals (Beijing) Co Gross Margin % Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.

Executives

Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you
Cmb International Investment Management Limited	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Headlines

No Headlines